Research Institute for Medicines and Pharmaceutical Sciences (iMed.UL), University of Lisbon, Portugal.
Ann Pharmacother. 2013 Nov;47(11):1498-506. doi: 10.1177/1060028013501802. Epub 2013 Sep 27.
Pharmacy practice studies have been criticized for presenting poor intervention description, which has serious implications when attempting to replicate interventions elsewhere. Evidence of improved outcomes for patients with chronic kidney disease (CKD) following pharmacist intervention exist in the literature, but similar concerns with intervention description have been raised.
To assess the implementability of evidence-based clinical pharmacist interventions in patients with CKD, based on the information contained in the published manuscripts.
PubMed was searched to retrieve systematic reviews addressing the role of pharmacists in patients with CKD. Primary studies describing clinical pharmacy services in CKD were subsequently extracted. To describe and characterize pharmacists' interventions, the DEPICT (Descriptive Elements of Pharmacist Intervention Characterization Tool) was applied. Studies were independently classified as "implementable" or "nonimplementable" by 2 authors, based on whether they could be easily implemented into practice using the description provided in the article. Finally, implementable interventions were grouped in different areas.
Five reviews were retrieved, and 39 original studies were analyzed. Of these, 59.0% were classified as nonimplementable. Among implementable interventions, 6 evidence-based areas of pharmacist interventions were identified: anemia, renal osteodystrophy, and cardiovascular risk factors management, medication appropriateness evaluation and medication reconciliation, patient education and compliance, and cost containment.
Information contained in most articles reporting pharmacist interventions in CKD is not sufficient to ensure the implementation of the service in clinical practice. Pharmacy practice research articles should be written with the aim of improving clinical practice and not just showing the results of pharmacists' interventions.
药学实践研究因干预描述不佳而受到批评,这在试图在其他地方复制干预措施时会产生严重影响。文献中已有证据表明,药师干预可改善慢性肾脏病(CKD)患者的结局,但对干预描述的类似担忧也已提出。
根据已发表文献中的信息,评估基于循证的临床药师干预措施在 CKD 患者中的实施可行性。
检索 PubMed 以获取探讨药师在 CKD 患者中作用的系统评价。随后提取描述 CKD 中临床药学服务的原始研究。为了描述和表征药师的干预措施,应用了 DEPICT(药师干预特征描述工具)。两位作者根据文章中提供的描述,独立将研究分为“可实施”或“不可实施”。最后,将可实施的干预措施分为不同的领域。
共检索到 5 篇综述,分析了 39 项原始研究。其中,59.0%的研究被归类为不可实施。在可实施的干预措施中,确定了 6 个基于证据的药师干预领域:贫血、肾性骨营养不良和心血管危险因素管理、药物适宜性评估和药物重整、患者教育和依从性、以及成本控制。
报告 CKD 中药师干预措施的大多数文章中的信息不足以确保该服务在临床实践中的实施。药学实践研究文章的撰写应旨在改善临床实践,而不仅仅是展示药师干预的结果。